elecell
elecell’s Research on Reactive Oxygen Species Removal Technology for Wound Healing Published in a Leading International Biomaterials Journal (BioactiveMaterials, IF=18.0)
elecell’s Research on Reactive Oxygen Species Removal Technology for Wound Healing Published in a Leading International Biomaterials Journal
The Korean biotech company eleccell (CEO Hyung-seop Han) announced on February 14, 2025, that it has published a scientific review paper on reactive oxygen species (ROS) removal technology, a key factor in wound healing, in Bioactive Materials, one of the top international journals in the biomaterials field.
The paper discusses various control technologies and scientific principles related to reactive oxygen species, which are known to be excessively generated at wound sites, causing tissue damage and delaying the healing process.
Paper link: https://doi.org/10.1016/j.bioactmat.2025.01.023
Let's talk .
Through this partnership, we can advance biomimetic current-based tissue regeneration and wound healing technologies and share groundbreaking solutions. Learn more about our partnership with Eleccell and join us as we strive to bring the world's first next-generation treatments to market.
Partnerships enable us to advance our biomimetic current-based tissue regeneration and wound healing technologies and distribute cutting-edge solutions. Discover more about partnering with elecell and join us in our mission to advance and deploy the world’s first next-generation therapies.
Let's talk .
Partnerships enable us to advance our biomimetic current-based tissue regeneration and wound healing technologies and distribute cutting-edge solutions. Discover more about partnering with elecell and join us in our mission to advance and deploy the world’s first next-generation therapies.